CRMI (08158) announces happy earnings, with an expected increase in shareholders' net profit for 2025 of no less than 28%.
China Regenerative Medicine (08158) announced that, compared to the same period in 2024, the group is expected to achieve an increase in profit attributable to owners of the company of no less than 28% for the year ending December 31, 2025. The increase in profit attributable to owners of the company is mainly due to the excess provision for income tax recognized in the 2025 fiscal year offsetting the tax.
CRMI(08158) announced that compared to the same period in 2024, the group expects the company's attributable surplus for the year ending December 31, 2025 to increase by no less than 28%. The expected increase in the company's attributable surplus is mainly due to the excess tax provision recognized in the 2025 fiscal year resulting in tax offset from previous years.
Related Articles
KAISA HEALTH (00876) released its annual performance with a net loss attributable to shareholders of HK$46.678 million, a 0.7% increase year-on-year.
NEP INTERLONG (08329) released its performance for the year 2025, with a net loss attributable to shareholders of 40.739 million yuan.
YUXING INFOTECH (08005) announced its performance for the year 2025. The company's owners' share of the loss was HK$64.213 million, an increase of 3.62% year-on-year.
KAISA HEALTH (00876) released its annual performance with a net loss attributable to shareholders of HK$46.678 million, a 0.7% increase year-on-year.
NEP INTERLONG (08329) released its performance for the year 2025, with a net loss attributable to shareholders of 40.739 million yuan.
YUXING INFOTECH (08005) announced its performance for the year 2025. The company's owners' share of the loss was HK$64.213 million, an increase of 3.62% year-on-year.
